{"id":2065,"date":"2007-12-01T23:25:38","date_gmt":"2007-12-01T22:25:38","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=2065"},"modified":"2013-09-12T16:01:56","modified_gmt":"2013-09-12T16:01:56","slug":"acid-reducing-agents-and-protese-inhibitors","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/2065","title":{"rendered":"Acid reducing agents and protese inhibitors"},"content":{"rendered":"<p><strong>HIV-druginteractions.org<\/strong><\/p>\n<p><strong>There have been two publications in October\u0092s HIV Medicine on this important topic.<\/strong><\/p>\n<p>Beique et al have provided a systematic review of all the available pharmacokinetic and clinical data on drug interactions between protease inhibitors and acid-reducing agents and their clinical consequences. The table documenting the interactions is a particularly valuable resource. [1]<\/p>\n<p>However, new data are constantly emerging and Luber et al have documented their findings on once daily fosamprenavir\/ritonavir and atazanavir\/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.<\/p>\n<p>This paper is an update of reference 12 cited by Beique et al \u0096 data initially presented at the Lisbon HIV Pharmacology Workshop in 2006. The major findings were:<\/p>\n<ul>\n<li>No impact of omeprazole on amprenavir exposure.<\/li>\n<li>Atazanavir AUC and Cmin reduced by 27%.<\/li>\n<li>4\/19 subjects experienced greater than 50% decline in both AUC and Cmin.<\/li>\n<\/ul>\n<p class=\"ref\">References:<\/p>\n<ol>\n<li>Beique L, Giguere P, la Porte C, Angel J. Interactions between protease inhibitors and acid-reducing agents: a systematic review. HIV Med, 2007, 8(6):335-345.<\/li>\n<li>Luber A, Brower R, Kim D, et al. Steady-state pharmacokinetics of once-daily fosamprenavir\/ritonavir and atazanavir\/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med, 2007, 8(7):457-464.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>HIV-druginteractions.org There have been two publications in October\u0092s HIV Medicine on this important topic. Beique et al have provided a systematic review of all the available pharmacokinetic and clinical data on drug interactions between protease inhibitors and acid-reducing agents and &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-2065","post","type-post","status-publish","format-standard","hentry","category-pk-and-drug-interactions"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=2065"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2065\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=2065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=2065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=2065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}